Randy Prescilla

Suggest Changes

Writes About:

Learn More
BACKGROUND Baricitinib, an oral selective inhibitor of Janus kinase (JAK)1 and JAK2, modulates pro-inflammatory cytokine signaling. OBJECTIVES The efficacy and safety of baricitinib were evaluated(More)